Sanofi Drug Shows Long-Term Benefit in Rare Disease
Blueprint Medicines, a Sanofi company, announced positive four-year data from its PIONEER study on the drug AYVAKIT. The results show a sustained benefit and long-term safety profile for patients with indolent systemic mastocytosis, a rare blood disorder.
Indolent systemic mastocytosis (ISM) is a rare blood disease caused by an overproduction of mast cells, a type of white blood cell. This accumulation can lead to a wide range of debilitating symptoms, including skin lesions, gastrointestinal issues like diarrhea and abdominal pain, and neurocognitive problems. The disease is driven in the vast majority of cases by a single genetic mutation known as KIT D816V. AYVAKIT (avapritinib) is a precision therapy designed as a potent inhibitor that specifically targets this mutation, addressing the underlying cause of the abnormal mast cell growth. The four-year PIONEER study data demonstrated that patients experienced sustained improvements in their overall symptoms and quality of life. For instance, in patients who had frequent diarrhea at the start of the study and remained on the drug for at least four years, the median reduction in diarrhea frequency was 65.6%. The long-term safety profile of AYVAKIT proved favorable, with a low discontinuation rate of just 3% due to treatment-related adverse events over a median follow-up of nearly four years. The most common side effects, such as edema, were typically mild. Recognizing the drug's potential, Sanofi acquired Blueprint Medicines in a deal valued at approximately $9.1 billion. This acquisition brought AYVAKIT, the only approved medicine for both advanced and indolent systemic mastocytosis, into Sanofi's immunology portfolio.
